Calidi Biotherapeutics (CLDI) Competitors $0.34 0.00 (-0.15%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI vs. OSTX, ANEB, BRNS, RNTX, BDRX, AADI, QNTM, RVPH, ATHE, and KRONShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include OS Therapies (OSTX), Anebulo Pharmaceuticals (ANEB), Barinthus Biotherapeutics (BRNS), Rein Therapeutics (RNTX), Biodexa Pharmaceuticals (BDRX), Aadi Bioscience (AADI), Quantum Biopharma (QNTM), Reviva Pharmaceuticals (RVPH), Alterity Therapeutics (ATHE), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Its Competitors OS Therapies Anebulo Pharmaceuticals Barinthus Biotherapeutics Rein Therapeutics Biodexa Pharmaceuticals Aadi Bioscience Quantum Biopharma Reviva Pharmaceuticals Alterity Therapeutics Kronos Bio OS Therapies (NYSE:OSTX) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability. Which has stronger valuation and earnings, OSTX or CLDI? OS Therapies has higher earnings, but lower revenue than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79M-$0.86-2.14Calidi Biotherapeutics$50K218.35-$29.22MN/AN/A Does the media favor OSTX or CLDI? In the previous week, OS Therapies had 3 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 3 mentions for OS Therapies and 0 mentions for Calidi Biotherapeutics. OS Therapies' average media sentiment score of 0.00 equaled Calidi Biotherapeutics'average media sentiment score. Company Overall Sentiment OS Therapies Neutral Calidi Biotherapeutics Neutral Do institutionals & insiders have more ownership in OSTX or CLDI? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 13.8% of OS Therapies shares are owned by company insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer OSTX or CLDI? OS Therapies presently has a consensus price target of $18.00, indicating a potential upside of 878.26%. Calidi Biotherapeutics has a consensus price target of $10.00, indicating a potential upside of 2,812.06%. Given Calidi Biotherapeutics' higher probable upside, analysts clearly believe Calidi Biotherapeutics is more favorable than OS Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in OSTX or CLDI? OS Therapies received 13 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformOS TherapiesOutperform Votes13100.00% Underperform VotesNo VotesCalidi BiotherapeuticsN/AN/A Is OSTX or CLDI more profitable? Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% Calidi Biotherapeutics N/A N/A -344.45% SummaryOS Therapies beats Calidi Biotherapeutics on 7 of the 11 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$10.92M$3.12B$5.61B$19.87BDividend YieldN/A1.56%5.28%3.83%P/E RatioN/A32.9027.1435.60Price / Sales218.35466.20411.8343.81Price / CashN/A168.6838.2517.51Price / Book-0.153.427.064.85Net Income-$29.22M-$72.35M$3.23B$1.02B7 Day Performance-3.70%7.27%2.67%1.94%1 Month Performance-22.62%17.53%8.82%3.02%1 Year PerformanceN/A-17.27%31.44%9.87% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics1.5297 of 5 stars$0.34-0.1%$10.00+2,812.1%N/A$10.92M$50K0.0038OSTXOS Therapies1.8855 of 5 stars$1.56+2.0%$18.00+1,053.8%N/A$43.83MN/A-1.81N/AAnalyst ForecastANEBAnebulo Pharmaceuticals3.0985 of 5 stars$1.06+1.3%$5.50+419.8%-42.6%$43.48MN/A-3.784Positive NewsBRNSBarinthus Biotherapeutics2.86 of 5 stars$1.07-0.9%$5.17+382.9%-46.1%$43.05M$14.97M-0.72107RNTXRein TherapeuticsN/A$1.93-1.0%N/AN/A$42.76MN/A-0.629Positive NewsGap DownBDRXBiodexa Pharmaceuticals0.5211 of 5 stars$1.15+6.5%N/AN/A$42.03M$83K0.0020Short Interest ↑AADIAadi Bioscience0.6014 of 5 stars$1.69-6.1%$1.67-1.4%+15.0%$41.74M$25.07M-0.7440Gap UpQNTMQuantum BiopharmaN/A$15.20+12.9%N/AN/A$41.13MN/A-0.99N/APositive NewsRVPHReviva Pharmaceuticals2.5458 of 5 stars$0.88-9.3%$9.00+922.7%-46.8%$41.13MN/A-0.795Gap UpATHEAlterity Therapeutics2.1712 of 5 stars$4.60+2.2%$12.00+160.9%+146.1%$40.79MN/A0.0010KRONKronos Bio3.3121 of 5 stars$0.67-1.0%$1.63+143.1%-24.2%$40.76M$9.19M-0.47100Short Interest ↑ Related Companies and Tools Related Companies OS Therapies Competitors Anebulo Pharmaceuticals Competitors Barinthus Biotherapeutics Competitors Rein Therapeutics Competitors Biodexa Pharmaceuticals Competitors Aadi Bioscience Competitors Quantum Biopharma Competitors Reviva Pharmaceuticals Competitors Alterity Therapeutics Competitors Kronos Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 6/12/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLDI Stock Free CLDI Stock Alerts